AU689452B2 - Conjugate vaccine against group B streptococcus - Google Patents

Conjugate vaccine against group B streptococcus

Info

Publication number
AU689452B2
AU689452B2 AU56654/94A AU5665494A AU689452B2 AU 689452 B2 AU689452 B2 AU 689452B2 AU 56654/94 A AU56654/94 A AU 56654/94A AU 5665494 A AU5665494 A AU 5665494A AU 689452 B2 AU689452 B2 AU 689452B2
Authority
AU
Australia
Prior art keywords
group
streptococcus
protein
derivative
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU56654/94A
Other languages
English (en)
Other versions
AU5665494A (en
Inventor
Frederick M. Ausubel
Dennis L Kasper
Lawrence C Madoff
James L Michel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
General Hospital Corp
Original Assignee
Brigham and Womens Hospital Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, General Hospital Corp filed Critical Brigham and Womens Hospital Inc
Publication of AU5665494A publication Critical patent/AU5665494A/en
Priority to AU56269/98A priority Critical patent/AU722078B2/en
Application granted granted Critical
Publication of AU689452B2 publication Critical patent/AU689452B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU56654/94A 1992-11-02 1993-11-02 Conjugate vaccine against group B streptococcus Ceased AU689452B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56269/98A AU722078B2 (en) 1992-11-02 1998-02-23 Conjugate vaccine against group B Streptococcus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02
US968866 1992-11-02
PCT/US1993/010506 WO1994010317A2 (en) 1992-11-02 1993-11-02 Conjugate vaccine against group b streptococcus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU56269/98A Division AU722078B2 (en) 1992-11-02 1998-02-23 Conjugate vaccine against group B Streptococcus

Publications (2)

Publication Number Publication Date
AU5665494A AU5665494A (en) 1994-05-24
AU689452B2 true AU689452B2 (en) 1998-04-02

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56654/94A Ceased AU689452B2 (en) 1992-11-02 1993-11-02 Conjugate vaccine against group B streptococcus

Country Status (14)

Country Link
EP (1) EP0669985A1 (fi)
JP (1) JPH08505282A (fi)
KR (1) KR100349331B1 (fi)
AU (1) AU689452B2 (fi)
CA (1) CA2146926A1 (fi)
FI (1) FI951979A (fi)
HU (1) HU220198B (fi)
IL (1) IL107458A0 (fi)
NO (1) NO951629L (fi)
NZ (1) NZ258684A (fi)
PL (1) PL177302B1 (fi)
RU (1) RU2209247C2 (fi)
WO (1) WO1994010317A2 (fi)
ZA (1) ZA938171B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
EP1100920A2 (en) * 1998-07-27 2001-05-23 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
EA009885B1 (ru) * 1998-12-22 2008-04-28 Майкросайенс Лимитед Применение пептидов бактерий streptococcus группы b, кодирующего их полинуклеотида, вакцина и антитело
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
GB9910375D0 (en) 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
JP4102186B2 (ja) 2000-10-13 2008-06-18 アイディー バイオメディカル コーポレイション グループｂストレプトコッカスのｂｖｈ−ａ２及びｂｖｈ−ａ３抗原
BRPI0408167B1 (pt) * 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
CA2684494C (en) 2007-04-16 2016-07-05 Lunds Universitets Utvecklingsaktiebolag Fusion protein capable of eliciting protective immunity against group b streptococcus
AU2009286956B2 (en) 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
CA3001433A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
WO2017114655A1 (en) 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006267A1 (en) * 1986-04-16 1987-10-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
WO1991004049A1 (en) * 1989-09-15 1991-04-04 The General Hospital Corporation CONJUGATE VACCINE FOR GROUP B $i(STREPTOCOCCUS)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006267A1 (en) * 1986-04-16 1987-10-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
WO1991004049A1 (en) * 1989-09-15 1991-04-04 The General Hospital Corporation CONJUGATE VACCINE FOR GROUP B $i(STREPTOCOCCUS)

Also Published As

Publication number Publication date
CA2146926A1 (en) 1994-05-11
KR950704492A (ko) 1995-11-20
NO951629D0 (no) 1995-04-28
ZA938171B (en) 1995-03-07
RU2209247C2 (ru) 2003-07-27
JPH08505282A (ja) 1996-06-11
NZ258684A (en) 1997-04-24
AU5665494A (en) 1994-05-24
HUT70981A (en) 1995-11-28
EP0669985A1 (en) 1995-09-06
NO951629L (no) 1995-07-03
PL308555A1 (en) 1995-08-21
FI951979A0 (fi) 1995-04-26
IL107458A0 (en) 1994-02-27
KR100349331B1 (ko) 2003-01-06
FI951979A (fi) 1995-06-29
WO1994010317A3 (en) 1994-07-07
WO1994010317A2 (en) 1994-05-11
HU220198B (hu) 2001-11-28
PL177302B1 (pl) 1999-10-29

Similar Documents

Publication Publication Date Title
US6342223B1 (en) Immunogenic composition for group B Streptococcus
AU689452B2 (en) Conjugate vaccine against group B streptococcus
EP0571538B1 (en) Structural gene of pneumococcal protein
US6426074B1 (en) Group B Streptococcus vaccine
AU693175B2 (en) Epitopic regions of pneumococcal surface protein A
EP0491865B1 (en) Conjugate vaccine for group b streptococcus
CA1341334C (en) Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
AU722078B2 (en) Conjugate vaccine against group B Streptococcus
AU667668C (en) Structural gene of pneumococcal protein